Eddie Pharmaceuticals: Plans to acquire 22.2324% equity of Nanda Pharmaceuticals for 130 million yuan.

Eddie Pharmaceutical announced that it plans to acquire 22.2324% equity held by minority shareholders of its subsidiary Nanjing Nanda Pharmaceutical Co., Ltd. at a price of 130 million yuan. After the acquisition is completed, the company's direct shareholding in Nanda Pharmaceutical will increase from 51.1256% to 73.3580%. The price of this transaction is based on an evaluation report issued by Shen Evaluation Consulting Co., Ltd., a qualified asset evaluation agency for securities and futures related business, and was reached through friendly negotiations among the parties involved in the transaction. According to the asset evaluation report "Nanjing Nanda Pharmaceutical Co., Ltd. Shareholder's Full Equity Value" (Shen Evaluation Report No. 2026-0001) as of October 31, 2025, the assessed value of Nanda Pharmaceutical's full equity for shareholders is 585 million yuan.